Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell malignancy, have dramatically improved. The development of the immunomodulatory drugs (IMiDs), which include thalidomide, lenalidomide, and pomalidomide, has contributed significantly to these improved outcomes...

Full description

Saved in:

Bibliographic Details
Published in:	Drugs (New York, N.Y.) Vol. 77; no. 5; pp. 505 - 520
Main Authors:	Holstein, Sarah A., McCarthy, Philip L.
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01.04.2017 Springer Nature B.V
Subjects:	Angiogenesis Chemotherapy Cytotoxicity Drug development Drug dosages Drugs FDA approval Health risk assessment Humans Immunologic Factors - therapeutic use Immunomodulation Immunomodulators Internal Medicine Lenalidomide Leprosy Leukemia Malignancy Medical prognosis Medicine Medicine & Public Health Molecular modelling Molecular structure Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Patients Pharmacology/Toxicology Pharmacotherapy Review Article Stem cells Structure-function relationships Studies Thalidomide Thalidomide - analogs & derivatives Thalidomide - therapeutic use Thromboembolism Thrombosis Topical Collection on Immuno-Oncology Transcription factors Transplants & implants Ubiquitination Acute Myeloid Leukemia Bortezomib Natural Killer Cell Myeloma Thalidomide
ISSN:	0012-6667, 1179-1950, 1179-1950
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!